Thomas Woiwode, PhD

Tom Woiwode is a Managing Director who has been with Versant Ventures since 2002. Most recently, Tom served as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. Tom led the process that culminated in the sale of Okairos to GSK for $325M.

Prior to his role with Okairos, Tom co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with Biotie), and Amira (acquired by BMS for up to $475M).

Tom was also Principal at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. In addition, Tom was a research scientist at XenoPort before joining Versant.


Cristina LeClerc


Being a native Californian and surfer, you can often find Tom at the nearest beach trying to catch the next great wave. Tom resides in Basel, Switzerland with his wife and two daughters. Collectively as a family, with Europe as their backyard, they enjoy traveling the world together in search for Tom’s perfect wave.